BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22580607)

  • 1. The genesis and unique properties of the lymphovascular tumor embolus are because of calpain-regulated proteolysis of E-cadherin.
    Ye Y; Tian H; Lange AR; Yearsley K; Robertson FM; Barsky SH
    Oncogene; 2013 Mar; 32(13):1702-13. PubMed ID: 22580607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early to intermediate steps of tumor embolic formation involve specific proteolytic processing of E-cadherin regulated by Rab7.
    Ye Y; Gao JX; Tian H; Yearsley K; Lange AR; Robertson FM; Barsky SH
    Mol Cancer Res; 2012 Jun; 10(6):713-26. PubMed ID: 22638108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E-cadherin accumulation within the lymphovascular embolus of inflammatory breast cancer is due to altered trafficking.
    Ye Y; Tellez JD; Durazo M; Belcher M; Yearsley K; Barsky SH
    Anticancer Res; 2010 Oct; 30(10):3903-10. PubMed ID: 21036701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geometric tumor embolic budding characterizes inflammatory breast cancer.
    Modi AP; Nguyen JPT; Wang J; Ahn JS; Libling WA; Klein JM; Mazumder P; Barsky SH
    Breast Cancer Res Treat; 2023 Feb; 197(3):461-478. PubMed ID: 36473978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma.
    Tomlinson JS; Alpaugh ML; Barsky SH
    Cancer Res; 2001 Jul; 61(13):5231-41. PubMed ID: 11431364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma.
    Alpaugh ML; Tomlinson JS; Kasraeian S; Barsky SH
    Oncogene; 2002 May; 21(22):3631-43. PubMed ID: 12032865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma.
    Alpaugh ML; Tomlinson JS; Ye Y; Barsky SH
    Am J Pathol; 2002 Aug; 161(2):619-28. PubMed ID: 12163386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Truncated E-cadherin potentiates cell death in prostate epithelial cells.
    Rios-Doria J; Day ML
    Prostate; 2005 May; 63(3):259-68. PubMed ID: 15538719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gain in cellular organization of inflammatory breast cancer: A 3D in vitro model that mimics the in vivo metastasis.
    Morales J; Alpaugh ML
    BMC Cancer; 2009 Dec; 9():462. PubMed ID: 20028562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible model of spheroid formation allows for high efficiency of gene delivery ex vivo and accurate gene assessment in vivo.
    Alpaugh ML; Barsky SH
    Hum Gene Ther; 2002 Jul; 13(10):1245-58. PubMed ID: 12133277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells.
    Rios-Doria J; Day KC; Kuefer R; Rashid MG; Chinnaiyan AM; Rubin MA; Day ML
    J Biol Chem; 2003 Jan; 278(2):1372-9. PubMed ID: 12393869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lymphovascular embolus of inflammatory breast cancer exhibits a Notch 3 addiction.
    Xiao Y; Ye Y; Zou X; Jones S; Yearsley K; Shetuni B; Tellez J; Barsky SH
    Oncogene; 2011 Jan; 30(3):287-300. PubMed ID: 20838375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
    Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer.
    Trillsch F; Kuerti S; Eulenburg C; Burandt E; Woelber L; Prieske K; Eylmann K; Oliveira-Ferrer L; Milde-Langosch K; Mahner S
    Br J Cancer; 2016 Jan; 114(2):213-20. PubMed ID: 26757261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin.
    Zuo JH; Zhu W; Li MY; Li XH; Yi H; Zeng GQ; Wan XX; He QY; Li JH; Qu JQ; Chen Y; Xiao ZQ
    J Cell Biochem; 2011 Sep; 112(9):2508-17. PubMed ID: 21557297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The morphogenic function of E-cadherin-mediated adherens junctions in epithelial ovarian carcinoma formation and progression.
    Wu C; Cipollone J; Maines-Bandiera S; Tan C; Karsan A; Auersperg N; Roskelley CD
    Differentiation; 2008 Feb; 76(2):193-205. PubMed ID: 17608733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation in vivo of the invasion-suppressor molecule E-cadherin in experimental and clinical cancer.
    Mareel M; Vleminckx K; Vermeulen S; Yan G; Bracke M; van Roy F
    Princess Takamatsu Symp; 1994; 24():63-80. PubMed ID: 8983064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast carcinomatous tumoral emboli can result from encircling lymphovasculogenesis rather than lymphovascular invasion.
    Mahooti S; Porter K; Alpaugh ML; Ye Y; Xiao Y; Jones S; Tellez JD; Barsky SH
    Oncotarget; 2010 Jun; 1(2):131-147. PubMed ID: 21297224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E-cadherin suppression accelerates squamous cell carcinoma progression in three-dimensional, human tissue constructs.
    Margulis A; Zhang W; Alt-Holland A; Crawford HC; Fusenig NE; Garlick JA
    Cancer Res; 2005 Mar; 65(5):1783-91. PubMed ID: 15753375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells.
    Symowicz J; Adley BP; Gleason KJ; Johnson JJ; Ghosh S; Fishman DA; Hudson LG; Stack MS
    Cancer Res; 2007 Mar; 67(5):2030-9. PubMed ID: 17332331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.